Blog: ATAI LIFE SCIENCES N.V. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain

(b) On June 15, 2022 (the “Notice Date”), Greg Weaver, Chief Financial Officer
of ATAI Life Sciences N.V. (the “Company”) and ATAI Life Sciences US, Inc.
(“ATAI US”), entered into a Transition and Separation Agreement with the Company
and ATAI US (the “Transition Agreement”) pursuant to which Mr. Weaver will
resign from his current positions and support in the transition of duties to his
successor as further described below. Mr. Weaver will continue serving as the
Company’s Chief Financial Officer during the Transition Term (as defined below).

(c) During the Transition Term Stephen Bardin will serve as the Company’s Deputy
CFO and CFO Designate and will subsequently be appointed as the Company’s Chief
Financial Officer effective during the third quarter of 2022, but in any event
no later than September 30, 2022, as determined by the Supervisory Board.

Mr. Bardin, age 32, is expected to commence his employment with the Company as
Deputy CFO and CFO Designate effective June 27, 2022. Prior to joining the
Company, Mr. Bardin served in various capacities at BridgeBio Pharma, Inc.
(“BridgeBio”), a commercial-stage biopharmaceutical company, most recently as
its Senior Vice President, Finance and Operations, from October 2019 until June
2022. Prior to that, Mr. Bardin served as Director, Corporate Development and
Associate Director, Corporate Development at Myovant Sciences Ltd., a
biopharmaceutical company, from July 2017 – October 2019. Prior to that,
Mr. Bardin served as a Consultant at The Boston Consulting Group from August
2011 – May 2014 and September 2016 – July 2017. Mr. Bardin received his Master
of Business Administration from Stanford Graduate School of Business and his
Bachelor of Science in Engineering in biomedical engineering from Duke

At this time, there are no arrangements or understandings between Mr. Bardin and
any other persons pursuant to which he is to be appointed as Chief Financial
Officer of the Company. Any changes to Mr. Bardin’s compensatory arrangements in
connection with his future appointment as Chief Financial Officer will be filed
in an amendment to this Current Report on Form 8-K after such information is
determined or becomes available. Mr. Bardin has no family relationships with any
executive officer or director of the Company. There are no transactions in which
Mr. Bardin has an interest requiring disclosure under Item 404(a) of Regulation
S-K currently contemplated or since the beginning of the last fiscal year.

(e) Pursuant to the Transition Agreement, Mr. Weaver will continue to be
employed as Chief Financial Officer through the earlier of (i) September 30,
2022 and (ii) the date Mr. Weaver is notified in writing that a new Chief
Financial Officer is appointed and ready to serve in such capacity (the
“Resignation Date” and such term, the “Transition Term”). In addition, from the
Resignation Date through March 31, 2023 (the “Advisory Term”), Mr. Weaver will
serve as a non-employee advisor to assist in the transition of duties to the new
Chief Financial Officer (the “Advisory Services”).

The Transition Agreement provides compensation for such services as follows:

         •   During the Transition Term, Mr. Weaver will continue to (i) receive
             his annual base salary of $400,000 (the "Current Base Salary"), (ii)
             participate in the employee benefit plans and programs of ATAI US,
             subject to the terms and conditions of such plans and programs and
             (iii) vest in his outstanding Company option awards. Subject to
             Mr. Weaver remaining continuously employed through the Resignation
             Date, executing a general release of claims, and completing his
             services during the Transition Term to the good faith reasonable
             satisfaction of ATAI US, Mr. Weaver will also be eligible to receive
             an annual bonus for calendar year 2022 in an amount equal to $160,000,
             pro-rated based on achievement of certain performance milestones for
             the year, as determined by the board of directors of the Company.

         •   During the Advisory Term, Mr. Weaver will be paid an advisory fee at
             an annual rate equal to 25% of the Current Base Salary, pro-rated for
             any partial period of service; provided that, any Advisory Services
             performed in excess of forty (40) hours per month shall, so long as
             pre-approved by ATAI US, be payable at an hourly rate of $450, and
             will continue to vest in 25% of his outstanding Company option awards.
             Provided that (i) the Advisory Term is not terminated by ATAI US for
             "cause" or due to Mr. Weaver's material breach of the Transition
             Agreement, (ii) Mr. Weaver completes the Advisory Services to the
             reasonable satisfaction of ATAI US and (iii) Mr. Weaver timely
             executes a general release of claims, the right to exercise
             Mr. Weaver's vested options will be extended until the one-year
             anniversary of the expiration of the Advisory Term.

The foregoing description of the Transition Agreement does not purport to be
complete and is subject to, and qualified in its entirety by, the full text of
the Transition Agreement, a copy of which is filed as Exhibit 10.1 hereto and is
incorporated by reference herein.

Item 7.01 Regulation FD Disclosure

On June 17, 2022, the Company issued a press release announcing executive
changes described above. A copy of the press release is attached as Exhibit 99.1
and incorporated herein by reference.

The information contained under Item 7.01 of this Current Report on Form 8-K
(including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act except as may be expressly set forth by specific
reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  No.                                     Description

10.1           Transition and Separation Agreement, dated June 15, 2022, by and
             among ATAI Life Sciences US, Inc., ATAI Life Sciences N.V. and Greg

99.1           Press Release, dated June 17, 2022*

104          Cover Page Interactive Data File (embedded within the inline XBRL

+ Management contract or compensatory plan, contract or arrangement.

* Furnished herewith


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s